- Home
- GHI vs CLYM Comparison
GHI vs CLYM Comparison
Compare GHI & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- CLYM
- Stock Information
- Founded
- GHI 1998
- CLYM 2018
- Country
- GHI United States
- CLYM United States
- Employees
- GHI N/A
- CLYM N/A
- Industry
- GHI Finance: Consumer Services
- CLYM
- Sector
- GHI Finance
- CLYM
- Exchange
- GHI Nasdaq
- CLYM NYSE
- Market Cap
- GHI 287.2M
- CLYM 242.8M
- IPO Year
- GHI N/A
- CLYM 2021
- Fundamental
- Price
- GHI $11.44
- CLYM $3.01
- Analyst Decision
- GHI Strong Buy
- CLYM
- Analyst Count
- GHI 4
- CLYM 0
- Target Price
- GHI $17.50
- CLYM N/A
- AVG Volume (30 Days)
- GHI 111.8K
- CLYM 338.5K
- Earning Date
- GHI 11-06-2024
- CLYM 11-12-2024
- Dividend Yield
- GHI 12.96%
- CLYM N/A
- EPS Growth
- GHI N/A
- CLYM N/A
- EPS
- GHI 0.61
- CLYM N/A
- Revenue
- GHI $34,307,528.00
- CLYM N/A
- Revenue This Year
- GHI N/A
- CLYM N/A
- Revenue Next Year
- GHI $5.53
- CLYM N/A
- P/E Ratio
- GHI $18.62
- CLYM N/A
- Revenue Growth
- GHI 1.47
- CLYM N/A
- 52 Week Low
- GHI $10.92
- CLYM $2.35
- 52 Week High
- GHI $17.48
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- GHI 34.67
- CLYM N/A
- Support Level
- GHI $10.92
- CLYM N/A
- Resistance Level
- GHI $11.55
- CLYM N/A
- Average True Range (ATR)
- GHI 0.45
- CLYM 0.00
- MACD
- GHI -0.06
- CLYM 0.00
- Stochastic Oscillator
- GHI 25.00
- CLYM 0.00
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.